



Kansas City, Missouri (N=300)

Figure A. Age of GISP participants, in years, 2010




Kansas City, Missouri (N=300)

Figure B. Race/ethnicity of GISP participants, 2010



Kansas City, Missouri


Figure C. Percentage of GISP participants identifying as men who have sex with men, 2000-2010*



*Note: Site participated in GISP from 2000-2001 and 2007-2010.


Kansas City, Missouri (N=300)

Figure D. Drugs used to treat gonorrhea among GISP participants, 2010




Kansas City, Missouri (N=300)

Figure E. Drugs used to treat *Chlamydia trachomatis* infection among GISP participants, 2010




Kansas City, Missouri (N=300)

Figure F. Resistance to penicillin, tetracycline, and ciprofloxacin among GISP isolates, 2010



Kansas City, Missouri


Figure G. Distribution of Minimum Inhibitory Concentrations (MICs) to ceftriaxone among GISP isolates, 2006-2010*



Note: Site participated in GISP from 2007-2010.

Kansas City, Missouri


Figure H. Distribution of Minimum Inhibitory Concentrations (MICs) to cefixime among GISP isolates, 2006 and 2009-2010*



NOTE: Isolates were not tested for cefixime susceptibility in 2007 and 2008. Site participated in GISP from 2007-2010.

Kansas City, Missouri


Figure I. Intermediate resistance and resistance to ciprofloxacin among GISP isolates, 1990-2010*



Note: Susceptibility to ciprofloxacin first measured in 1990. Site participated in GISP from 1991-2001 and 2007-2010.

Kansas City, Missouri

Figure J. Distribution of Minimum Inhibitory Concentrations (MICs) to azithromycin among GISP isolates, 2006-2010*



Note: Site participated in GISP from 2007-2010.